International Journal of Endocrinology / 2014 / Article / Tab 3

Review Article

A Review on the Relationship between SGLT2 Inhibitors and Cancer

Table 3

Incidence rates of bladder and breast cancer with canagliflozin exposure.

CanagliflozinSubjects with events (%)Rate per 1000 patient-year

Bladder Cancer
Canagliflozin 100 mg31392 (0.06)0.44
Canagliflozin 300 mg35063 (0.09)0.63
All canagliflozin66455 (0.07)
All noncanagliflozin36404 (0.11)0.84

Breast Cancer
Canagliflozin 100 mg13135 (0.38)2.61
Canagliflozin 300 mg15147 (0.46)3.39
All canagliflozin282712 (0.42)
All noncanagliflozin15016 (0.4)3.05

Source: reference [14], data obtained from 8 phase 3 clinical trials, data cutoff date: Nov 15, 2012.